Occult Breast Cancer Multi-Omics Study: Immune Landscape and Survival Data

A multi-omics dataset from figshare, last updated April 17, 2026, by author Junjie Liu. It integrates survival data from the SEER database (n=12,162) with molecular profiles from proteomics, bulk transcriptomics, and single-cell RNA sequencing to investigate immune mechanisms in occult breast cancer. The study characterizes the tumor microenvironment, focusing on B cell-mediated immune surveillance linked to patient prognosis.

Use Cases

• Validate survival outcomes for occult breast cancer based on SEER database analysis with propensity score matching.
• Identify B cell-related pathway upregulation using quantitative proteomic profiling data.
• Analyze cellular heterogeneity and intercellular communication within the tumor microenvironment using single-cell RNA sequencing and CellChat analysis.
• Correlate B cell infiltration levels from transcriptomic data with patient survival metrics.
• Investigate secretory signals and contact-dependent interactions (e.g., TNF, BAFF, CD40, MHC) orchestrating anti-tumor responses.

Strengths

• Integrates multiple data modalities: survival data from 12,162 SEER records, proteomics, bulk transcriptomics, and single-cell RNA sequencing.
• Study design includes propensity score matching for survival outcome validation.
• Dataset is openly available under a CC-BY-4.0 license.
• File size is 751.4 KB, indicating a focused, manageable dataset for analysis.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• Data may reflect bias inherent to the SEER database and the specific study cohort.
• The description notes findings are exploratory and pending functional validation in larger cohorts.

Provenance

Source

figshare, author Junjie Liu.

Collection Method

Data generated through integration of public SEER survival data and multi-omics profiling (proteomics, transcriptomics, scRNA-seq) of clinical samples.

Freshness

Last updated 2026-04-17 05:22:12.